H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift
H.C. Wainwright cut its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24 and kept a Buy rating. The stock trades at about $8.04. The firm cited Phase 3 CoMpass enrollment completion in June 2026 (108 patients) and expects topline data in 2H 2027, while shifting capital toward ocular oncology.
How this was made
The 30-second read
Why it matters
For traders, the actionable signal is the PT reduction ($18 vs $24) with a maintained Buy, alongside reiterated milestones: Phase 3 CoMpass enrollment completion (108 patients) and topline timing in 2H 2027.
Market read
This is primarily an analyst valuation update tied to a strategic shift in modeled capital allocation, with no new clinical readout disclosed.
What to watch
The article highlights a long cash runway into 1H 2029 and strong liquidity metrics, which can offset valuation pressure from PT reductions if investors focus on financing risk.
Background
The piece centers on an H.C. Wainwright price-target reduction for Aura Biosciences and summarizes the company’s clinical and capital-allocation plans across ocular oncology and bladder cancer.
Ticker impact
H.C. Wainwright cut Aura Biosciences’ price target to $18 from $24 while keeping a Buy rating, citing a strategic shift and updated program assumptions.
Near-term bias slightly negative versus prior PT, with volatility tied to 2H 2027 topline expectations.
The article provides a concrete PT reduction and links it to changes in modeled capital allocation and an out-licensing scenario for the bladder cancer program, while also reiterating trial enrollment completion and FDA-aligned SPA design.
Market effects
Reinforces that pre-revenue biotech valuation is sensitive to capital allocation and commercialization assumptions, not just trial progress.
Limited, US small-cap biotech-specific sentiment impact.
Low, no cross-border regulatory or partnership event disclosed.
Counterpoint
The PT cut may be more about modeling conservatism than fundamental deterioration, since the Phase 3 CoMpass enrollment is completed and FDA alignment on design is emphasized.
Key entities
- companyAura Biosciences
NASDAQ-listed pre-revenue biotech advancing belzupacap sarotalocan in Phase 3 CoMpass and other ocular oncology programs.
- analyst_firmH.C. Wainwright
Issued the price-target cut to $18 from $24 while maintaining a Buy rating.
- regulatorFDA
Aligned on Phase 3 CoMpass trial design, endpoints, and planned statistical analysis under an SPA agreement.
